I suspect MRKR is going to be one of those early buyout/high premium type of situations, since the technology is impressive and they really don't have the infrastructure to advance such a complex therapy rapidly. A Novartis, Celgene/BMS, or Amgen would though.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.